MedTrace Logo

Tacrolimus for Thrombocytopenia in SS

NCT05678335 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-01-10

No results posted yet for this study

Summary

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.

Conditions

  • Sjogren Syndrome With Other Organ Involvement

Interventions

DRUG

Hydroxychloroquine

Oral hydroxychloroquine 200mg twice daily for 12weeks.

DRUG

Tacrolimus

Oral Tacrolimus 1-2mg twice daily for 12 weeks.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-12-31
Completion
2024-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05678335 on ClinicalTrials.gov